Diabetes management platform companies Diasend and Glooko announced that it will merge into one company under the Glooko name to deliver the world’s premier diabetes management platform focused on making diabetes management easier for people with diabetes and the teams who care for them. In addition to its merger, the companies have raised $8M in equity financing, led by global venture capital firm Canaan Partners, to accelerate integration and sales efforts. Other investors include Social Capital, Samsung Ventures and Yogen Dalal, Glooko’s founder and partner emeritus at venture capital firm Mayfield fund.
Combined business now enables in-clinic and remote diabetes management across 4,000 diabetes health systems, 23 countries and 15 languages worldwide. The joint platform downloads data from more than 160 different devices – including glucose meters, insulin pumps, continuous glucose monitors (CGMs) and activity trackers, in total covering over 95% of diabetes devices used worldwide.
Together the joint solution enables support for people with diabetes during and in-between doctor visits, as well as in-office diabetes data uploads and analytics. Additionally, the products also provide smartphone enabled self-management and a population health platform that supports diabetes coaches around the world.
“This is without a doubt the best possible scenario for our two companies, as well as for patients and the care teams that serve them. From our standpoint, this means adding even more functionality to an already very strong technical platform,” says Anders Sonesson, CEO of Diasend AB.
Mountain View, CA-based Glooko seamlessly syncs with over 50 diabetes devices and major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and APIs offer diabetes-centric analytics and insightful reports, graphs and risk flags to health systems and payers.
Previously, Glooko’s recently launched its Glooko Advise product line is focused on leveraging diabetes data to deliver personalized medicine recommendations to patients and care teams.
Gothenburg, Sweden-based Diasend simplifies life for people with diabetes and facilitates the work of their health care providers by optimizing diabetes data management. The company’s comprehensive and market leading solution involves transmitting, storing and analyzing data from more than 140 different glucose meters, insulin pumps, CGM systems and leading activity trackers – allowing patients and caregivers to easily access the exact same information. Diasend recently partnered with Abbott’s Freestyle LibreLink patients to see their glucose data alongside pump data.
